IL17A and psoriasis: Modern treatment of psoriasis is aimed at reducing the symptoms of the disease and improving the quality of life of patients, including local therapy (vitamin D analogs, corticosteroids), phototherapy (narrowband ultraviolet-B radiation, psoralen, ultraviolet-A radiation), systemic immunomodulators (methotrexate, cyclosporine, acitretin), targeted biological agents (TNF-α, IL-17, IL-23 inhibitors), and oral small-molecule inhibitors (dimethyl fumarate, apremilast) [8,9].